All News
EULAR 2024 – Day 3 Report
EULAR treats its attendees to a wonderful lunch each day – Schnitzel, gnocchi, goulash at lunch after muffins and coffee in the morning. It's no wonder the meeting has been a lively one, well attended with a wealth of stimulating ideas, research and discussion. Here are a few of my favorite abstracts and presentations from today, day 3 in Vienna.
Read Article
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at #EULAR2024 in Vienna, Austria:
OP0195
LBA0005
POS0803
OP0138
https://t.co/MnefRxYqMh https://t.co/Mwq4s7eTKY
Dr. John Cush RheumNow ( View Tweet)
AI meets Rheumatology: ChatGPT and patient response optimization
Large language models like ChatGPT, trained on vast text data, are revolutionizing healthcare by understanding and generating human-like language.
https://t.co/GzT9UvndTX https://t.co/ziOh8oCbZ9
Dr. John Cush RheumNow ( View Tweet)
A beautiful free concert in Vienna
#EULAR2024 @eular_org @RheumNow https://t.co/8YPWbkmTUr
Janet Pope Janetbirdope ( View Tweet)
@RheumNow The always erudite @LCalabreseDO is no slouch of a debating opponent, however. He acknowledges that the science has been imperfect, too much is wrapped up in it, and that fibromyalgia can teach a lot to long COVID. #EULAR2024 @RheumNow https://t.co/TzR4SMZh9f
Links:
David Liew drdavidliew ( View Tweet)
@RheumNow @LCalabreseDO @NIH and Len gives us some key recommendations for better practice for long COVID - for me, equally as applicable to fibromyalgia as to long COVID.
Fantastic discussion #EULAR2024 @RheumNow https://t.co/8PnjPEKcOu
David Liew drdavidliew ( View Tweet)
😂😂😂I love this study so much. I guess , happy people live better.
#Eular2024 https://t.co/ChrdSgw51k
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
#IgG4 Pearls
Thanks for sharing
Isolated ⬆️ serum #IgG4 level
✅ How high? 5x ULN ➡️ PPV 75%
✅Typical organ(s) involved?
❓Another explanation
Dr Jone Stone
#Rheumatology #EULAR2024 https://t.co/UVKmH57iVM https://t.co/uxHBl0I3cM
Links:
Ask The Rheumatologist LastManStand85 ( View Tweet)
EULAR guidelines for screening for TB in rheumatic disease patients
#EULAR2024 https://t.co/jaixl8lGkY
Jilaine Bolek Berquist BolekBerqui ( View Tweet)
Setting a standard for imaging reporting in patients with suspected axial spondyloarthritis is an important part of our efforts toward improving the early and accurate diagnosis of SpA:
https://t.co/zYbcL1CaTP https://t.co/1jnBDBSDNv
Links:
Prof. Denis Poddubnyy DrPoddubnyy ( View Tweet)
NEW biomarkers in #MAS
1️⃣ IL-18 (available at some 🏥)⭐️
2️⃣ S100A12
3️⃣ CXCL9/10
🚨When suspecting #MAS, don’t ignore the possibility of a monogenic disorder!
🎙️ Dr. Sophie Georgin-Lavialle 🇫🇷
#macrophage
#EULAR2024
#genetics
#rheumx https://t.co/Uot3JjrWs8
Links:
Artem Minalyan, MD, DABOM AMinalyan ( View Tweet)
DMOADs in #osteoarthritis at #EULAR2024: 1) Tonia Vincent: StepUp OA endotype SF proteomics —> endothelial to mesenchymal transition proteins. 2) Phil Conaghan: proregenerative (& degeneration slowing) therapies in pipeline. 3) @Larhumato: novel RCT designs & structure outcomes
Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)
POS0277: proof of concept: Prophlx with canakinumab x 1 dose rather than steroids/colch/NSAIDS when starting pegloticase with MTX in pts with active, refractory gout: 11 pts: #gout flares 0 (compared 54% in MIRROR-C), infusion rxn 0, no safety signal @rheumnow https://t.co/4qFnQTOuq0
TheDaoIndex KDAO2011 ( View Tweet)
Recommendation for management of fatigue in people with rheumatic disease.
Considering fatigue as a surrogate for inflammation and changing medication accordingly is part of it.
I will also add yearly blood work including:
1- VitD
2-HBA1c and LDl
3-TsH. https://t.co/3QvPqMxZSN
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Enjoyed the #PolymyalgiaRheumatica session at #EULAR2024? Make sure to download our first atlas imaging article, where @drceowen, @drdavidliew et al. characterise PMR using whole-body PET/CT 👀
➡️ https://t.co/tbu0DgAFIS https://t.co/W06YbYyjRx
Links:
Rheumatology & Rheumatology Advances in Practice RheumJnl ( View Tweet)
Mapping the knee #osteoarthritis joint-nerve interactome — presented by @AM_Malf at #EULAR2024. Anatomical and molecular neuroplasticity occurs during OA onset + progression in the joint and DRG. Cool imaging of nerves and their activity with lightsheet microscopy in mice https://t.co/cre6LEVhle
Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)
Maintenance of remission in GPA/MPA.
RTX for 48 months sounds good to me.
#EULAR2024 https://t.co/5YGwOHhCuX
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Potential efficacy of JAK inhibitors in VEXAS syndrome
#EULAR2024
NZ https://t.co/HziLUgo1gA
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
500+ pts AxSPA
No difference in drug discontinuation between IL-17i, TNFi, IL23i over time
Adjusted for CRP, co-medication w/ MTX + classic covariates
IL-17i and IL-23i had experienced a higher number bDMARD failures
#EULAR2024 POS0259 @RheumNow https://t.co/F3B6uXyAca
Aurelie Najm AurelieRheumo ( View Tweet)
Cohort from Netherlands 400+ PsA pts IR first bioDMARD
300+ switched TNFi->IL-17i, 99 cycled TNFi->TNFi
3year retention rates
12 mo 75% cyclers 80% swappers
24mo 60% cyclers 56% swappers
No difference in treatment failure or DAS28 CRP
#EULAR2024 @RheumNow POS0278 https://t.co/J8ONjVAFqG
Aurelie Najm AurelieRheumo ( View Tweet)